Sorin V. Pislaru, M.D., Ph.D.

The purpose of this study is to assess the correlation between myocardial elasticity (ME) measurements obtained simultaneously during cardiac hemodynamic catheterization and intraprocedural echocardiography.

The purpose of this study is to evaluate the possibility of using echocardiography to measure heart muscle elasticity in clinical practice.

The purpose of this study is to assess the immediate effect of cardioversion on both the tricuspid and mitral annular dynamics and size in patients with atrial fibrillation, and to compare the annular dynamics and dimensions in both the tricuspid and mitral valves immediately before and after cardioversion in patients with atrial fibrillation using 3D transesophageal echocardiography.

The purpose of this study is is to assess the EPIQ-Affiniti and NG Compact ultrasound systems in a clinical environment and collect clinical data and feedback when compared to the site’s standard ultrasound system.

The purpose of this study is for evaluating an ultrasound-based technology (similar to standard clinical echocardiography) for measuring the stiffness of your heart muscle and your peripheral arteries. This type of information may prove to be clinically important.

The purpose of this study is to evaluate the number of leaks from the LA into the LAA, and the size of each. 

The purpose of this study is to measure the characteristics of the walls of an enlarged aortic blood vessel using non-invasive heart echo to help predict how quickly the enlargement may develop.

The purpose of this study is to determine if 3D volumetric measurements will allow more robust quantification of valvular heart disease severity.

The purpose of this study is to evaluate the severity of valvular lesions by using a new investigational imaging protocol. This new protocol includes 3D volumetric evaluation and is designed to see if such measurements are useful to be added to regular echo studies. An investigational image protocol means that the protocol is still experimental and isn’t approved by the U.S. Food and Drug Administration (FDA).

Classical echocardiographic assessment of heart valves is critical in determination of disease severity. However, echocardiography has only limited ability to predict how well an individual patient will do at time of surgery. New echocardiographic technology allows us to measure new, more refined parameters of your heart’s performance. This study is investigating whether these new parameters are better in predicting outcomes.

Compare transapical and transfemoral TAVR as regards clinical outcomes (both beneficial including improvement in heart failure class (NYHA) and reduced number of hospitalizations; and adverse including mortality and MACE.) Also, to compare cardiac mechanics’ outcomes in the short and intermediate follow up and correlate the baseline, percent change and final cardiac mechanics values with the clinical outcomes. So that this all comes down to being able to provide these information to the patients if there appeared to be a correlation between cardiac mechanics and clinical outcomes: